Clinical trial · Observational
Sonazoid Contrast-enhanced Ultrasound in Assessing Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer Patients.
NCT04657341CI-TRIAL-00048691unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of Sonazoid specific angiography and high mechanical index,the role of Sonazoid in assessing effectiveness of neoadjuvant chemotherapy in breast cancer patients was explored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ultrasound | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Sonazoid contrast-enhanced ultrasound in assessing effectiveness of neoadjuvant chemotherapy in breast cancer patients.
- timeFrame
- 10 months
- description
- Pathology as a gold standard,to compare the diagnostic performance between contrast-enhanced ultrasound and other contrast-enhanced imaging in neoadjuvant chemotherapy in breast cancer patients.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * (1) Refer to the guidelines and specifications for diagnosis and treatment of breast cancer, and it is clearly identified as breast cancer by pathological biopsy. * (2) Plan to implement NAC therapy; * (3) All patients and their family members signed informed consent forms, which were approved by the hospital medical Ethics Committee Exclusion Criteria: * (1) Those who are known to be allergic to ultrasound contrast agents; * (2)The subject has a history of allergy to eggs or egg products (i.e. skin rash, dyspnea, swelling of the mouth or throat, hypotension or shock, etc.) * (3) Intolerance to neoadjuvant chemotherapy; * (4) Poor compliance with chemotherapy treatment; * (5) Patients who cannot receive contrast agent MRI examination * (6) Arteriovenous (left and right) shunt patients in the heart and lungs; * (7) Mental disorders or mental disorders; * (8)Patients with serious heart disease or lung disease; * (9)Pet-pregnant, possibly pregnant or lactating; * (10)In addition, the researcher or the researcher thinks that the patient is not suitable to participate in this study.
References
Publications (0)
Data not yet available
No reference posted for this study.